Acalabrutinib – CALQUENCE® (USA)
According to the NCI website Acalabrutinib orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity.
Indicated according to Chemocare for:
- The treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
- The treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
More Information in English: